文献速递神经核医学

早发型阿尔茨海默病脑脊液生物标志物与脑代谢的关系

The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-08-28

研究纳入85例符合很可能早发型阿尔茨海默病(EOAD)标准的患者,行腰椎穿刺、脑18F-FDG PET和MRI,基于脑脊液AD生物标志物进行聚类分析。结果出现三个聚类:「Aβ42」聚类32例(Aβ42低、tau和p-tau正常)、「Aβ42+tau」聚类41例(Aβ42低、tau和p-tau高)、「tau」聚类12例(tau和p-tau很高、Aβ42低正常)。「Aβ42+tau」和「tau」聚类较「Aβ42」聚类额叶低代谢更明显,额叶代谢与脑脊液tau水平显著负相关;「Aβ42」和「Aβ42+tau」聚类较「tau」聚类左侧枕颞区低代谢更明显,该区代谢与脑脊液Aβ42水平显著正相关。

要点

  • 脑脊液生物标志物可区分EOAD患者中代谢不同的亚组。
  • 「Aβ42+tau」和「tau」聚类较「Aβ42」聚类额叶低代谢更明显。
  • 「Aβ42」和「Aβ42+tau」聚类较「tau」聚类左侧枕颞区低代谢更明显。

核心结论

  • 脑脊液生物标志物可用于识别早发型阿尔茨海默病中代谢不同的患者亚组。
  • 未来研究应探究这些生化差异是否具有临床后果。

研究设计与样本

  • 85例符合很可能早发型阿尔茨海默病(EOAD)标准的患者接受腰椎穿刺、脑18F-FDG PET和MRI。
  • 以脑脊液AD生物标志物为变量进行聚类分析,计算基于顶点的部分容积校正代谢图并在聚类间比较。
  • 评估每种脑脊液生物标志物与代谢图之间的线性相关性。

主要发现

  • 出现三个聚类:「Aβ42」聚类32例(Aβ42低、tau和p-tau正常)、「Aβ42+tau」聚类41例(Aβ42低、tau和p-tau高)、「tau」聚类12例(tau和p-tau很高、Aβ42低正常)。
  • 各聚类间年龄、性别比、教育水平、APOE基因型、病程或疾病严重程度无差异。
  • 「Aβ42+tau」和「tau」聚类较「Aβ42」聚类额叶低代谢更明显,额叶代谢与脑脊液tau水平显著负相关。
  • 「Aβ42」和「Aβ42+tau」聚类较「tau」聚类左侧枕颞区低代谢更明显,该区代谢与脑脊液Aβ42水平显著正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: One can reasonably suppose that cerebrospinal spinal fluid (CSF) biomarkers can identify distinct subgroups of Alzheimer's disease (AD) patients. In order to better understand differences in CSF biomarker patterns, we used FDG PET to assess cerebral metabolism in CSF-based subgroups of AD patients. METHODS: Eighty-five patients fulfilling the criteria for probable early-onset AD (EOAD) underwent lumbar puncture, brain 18F-FDG PET and MRI. A cluster analysis was performed, with the CSF biomarkers for AD as variables. Vertex-wise, partial-volume-corrected metabolic maps were computed for the patients and compared between the clusters of patients. Linear correlations between each CSF biomarker and the metabolic maps were assessed. RESULTS: Three clusters emerged. The "Aβ42" cluster contained 32 patients with low levels of Aβ42, while tau and p-tau remained within the normal range. The "Aβ42 + tau" cluster contained 41 patients with low levels of Aβ42 and high levels of tau and p-tau. Lastly, the "tau" cluster contained 12 patients with very high levels of tau and p-tau and low-normal levels of Aβ42. There were no inter-cluster differences in age, sex ratio, educational level, APOE genotype, disease duration or disease severity. The "Aβ42 + tau" and "tau" clusters displayed more marked frontal hypometabolism than the "Aβ42" cluster did, and frontal metabolism was significantly negatively correlated with the CSF tau level. The "Aβ42" and "Aβ42 + tau" clusters displayed more marked hypometabolism in the left occipitotemporal region than the "tau" cluster did, and metabolism in this region was significantly and positively correlated with the CSF Aβ42 level. CONCLUSION: The CSF biomarkers can be used to identify metabolically distinct subgroups of patients with EOAD. Future research should seek to establish whether these biochemical differences have clinical consequences.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jaillard A, Vanhoutte M, Maureille A, et al. The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2018. PMID: 30155553. doi:10.1007/s00259-018-4113-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。